Reshape Lifesciences Stock Probability of Future Stock Price Finishing Under 9.62
| RSLS Stock | USD 4.42 0.02 0.45% |
ReShape |
ReShape Lifesciences Target Price Odds to finish below 9.62
The tendency of ReShape Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 9.62 after 90 days |
| 4.42 | 90 days | 9.62 | close to 99 |
Based on a normal probability distribution, the odds of ReShape Lifesciences to stay under $ 9.62 after 90 days from now is close to 99 (This ReShape Lifesciences probability density function shows the probability of ReShape Stock to fall within a particular range of prices over 90 days) . Probability of ReShape Lifesciences price to stay between its current price of $ 4.42 and $ 9.62 at the end of the 90-day period is roughly 97.0 .
Given the investment horizon of 90 days ReShape Lifesciences has a beta of 0.3 indicating as returns on the market go up, ReShape Lifesciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding ReShape Lifesciences will be expected to be much smaller as well. Additionally ReShape Lifesciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. ReShape Lifesciences Price Density |
| Price |
Predictive Modules for ReShape Lifesciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as ReShape Lifesciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.ReShape Lifesciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. ReShape Lifesciences is not an exception. The market had few large corrections towards the ReShape Lifesciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold ReShape Lifesciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of ReShape Lifesciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.41 | |
β | Beta against Dow Jones | 0.30 | |
σ | Overall volatility | 0.56 | |
Ir | Information ratio | -0.07 |
ReShape Lifesciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of ReShape Lifesciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for ReShape Lifesciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| ReShape Lifesciences generated a negative expected return over the last 90 days | |
| ReShape Lifesciences has high historical volatility and very poor performance | |
| ReShape Lifesciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.68 M. Net Loss for the year was (11.39 M) with profit before overhead, payroll, taxes, and interest of 6.8 M. | |
| ReShape Lifesciences currently holds about 11.49 M in cash with (16.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| ReShape Lifesciences has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 109 shares by Thomas Stankovich of ReShape Lifesciences at 2.6 subject to Rule 16b-3 |
ReShape Lifesciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of ReShape Stock often depends not only on the future outlook of the current and potential ReShape Lifesciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. ReShape Lifesciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 102.7 K | |
| Cash And Short Term Investments | 4.5 M |
ReShape Lifesciences Technical Analysis
ReShape Lifesciences' future price can be derived by breaking down and analyzing its technical indicators over time. ReShape Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of ReShape Lifesciences. In general, you should focus on analyzing ReShape Stock price patterns and their correlations with different microeconomic environments and drivers.
ReShape Lifesciences Predictive Forecast Models
ReShape Lifesciences' time-series forecasting models is one of many ReShape Lifesciences' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary ReShape Lifesciences' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about ReShape Lifesciences
Checking the ongoing alerts about ReShape Lifesciences for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for ReShape Lifesciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| ReShape Lifesciences generated a negative expected return over the last 90 days | |
| ReShape Lifesciences has high historical volatility and very poor performance | |
| ReShape Lifesciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.68 M. Net Loss for the year was (11.39 M) with profit before overhead, payroll, taxes, and interest of 6.8 M. | |
| ReShape Lifesciences currently holds about 11.49 M in cash with (16.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| ReShape Lifesciences has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 109 shares by Thomas Stankovich of ReShape Lifesciences at 2.6 subject to Rule 16b-3 |
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.